Biotechnology - Licensing, Rare diseases


Current filters:

LicensingRare diseases

Popular Filters

uniQure signs up Medison to distribute Glybera in Israel

uniQure signs up Medison to distribute Glybera in Israel


Netherlands-based human gene therapy firm uniQure has entered an exclusive distribution agreement with…

BiotechnologyGlyberaLicensingMedison PharmaRare diseasesRest of the WorlduniQure

BioMarin buys rights to Repligen preclinical compounds


BioMarin Pharmaceuticals has entered into an agreement to purchase from fellow USA-based Repligen Corp…

BioMarin PharmaceuticalBiotechnologyLicensingRare diseasesRepligen

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa


UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products


French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23


Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Shire and Santaris extend strategic alliance


Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Acceleron and Shire not to restart ACE-031 program


Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol


Netherlands-based biotech firm Dezima Pharma says it has in-licensed a cholesteryl ester transfer protein…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaImaxioLicensingMitsubishi TanabeRare diseasesSpiroleptTrolovol

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Repligen in $70 million deal with Pfizer for SMA program


USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead


US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation


In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

Alnylam gets upfront $22.5 million in RNAi link with Genzyme


French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy


In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Pharming considers options, including a sale of the company


Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

Pharming in deal with Hyupjin for Ruconest in South Korea


Dutch biotech firm Pharming Group (NYSE Euronext: PHARM) has entered into an agreement with Seoul-based…

Asia-PacificBiotechnologyHyupjin CorpLicensingPharmingRare diseasesRhucinRuconest

Shire buys rights to arGEN-X technology for rare diseases


Dutch/Belgian preclinical stage biotech company arGEN-X, focused on the discovery and development of…

BiotechnologyLicensingPharmaceuticalRare diseases



Back to top